Loading...
•
Mar 31, 2020
IDEXX Q1 2020 Earnings Report
IDEXX reported revenue growth of 9% and EPS of $1.29, despite late-quarter impacts from COVID-19.
Key Takeaways
IDEXX Laboratories announced first quarter results with a 9% increase in revenue, reaching $626 million, driven by a 10% growth in Companion Animal Group (CAG) Diagnostics recurring revenue. EPS was reported at $1.29, a 10% increase. The company has withdrawn its 2020 guidance due to COVID-19 uncertainties.
Reported revenue growth of 9% driven by Companion Animal Group ("CAG") Diagnostics recurring revenue growth of 10%.
Delivered EPS of $1.29, representing 10% growth.
Enhanced liquidity by increasing credit facility to $1 billion and issuing $200 million in fixed-rate notes.
Withdrew 2020 guidance due to the unpredictability of the impacts from the COVID-19 pandemic.
IDEXX
IDEXX
IDEXX Revenue by Segment
IDEXX Revenue by Geographic Location
Revenue by Segment
VetLab Consumables Revenue
CapyFin.comRapid Assay Products Revenue
CapyFin.comReference Labs Revenue
CapyFin.comVet Software & Imaging Revenue
CapyFin.comWater Segment Revenue
CapyFin.comLivestock, Poultry, Dairy Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company is withdrawing its previously announced full year 2020 guidance due to the unpredictability of the duration and the magnitude of impacts from the COVID-19 pandemic on veterinary service providers.
Revenue & Expenses
Visualization of income flow from segment revenue to net income